Neuro - Believe it or not, the discussion has been very civil the past several days.
COR investors are understandably very upset right now at the prospect of the authorized share count being doubled from 100M to 200M.
The prevailing sentiment by far on the board the past few days since the Special Meeting PR is that COR investors are tired to the point of throwing in the towel if Cortex doesn't have a reasonably significant deal to announce prior to the vote.
I personally am to the point where I just want to see Ampakines developed by a company with sufficient resources, and I don't foresee Cortex being able to do that within the next few years, if ever. That is mostly a commentary on Cortex's perpetually cash-strapped status and not a comment on Cortex's mgmt or the bad luck which I believe they have clearly suffered.
But regardless of the reasons, Ampakines have languished long enough and need to get into the hands of companies who can realistically advance them toward eventual commercialization.
Market Data 
Markets 
AI
